Neurocrine Biosciences uncommon illness drug presumably tied to issues of safety
Adam Feuerstein is a senior author and biotech columnist, reporting on the crossroads of drug improvement, enterprise, Wall Road, and ...
Tag: Biosciences
Argenx Expands Immunology Portfolio with $2.2B Buyout of Forte Biosciences
Argenx has agreed to amass Forte Biosciences for $2.2 billion, the businesses stated, in a deal supposed to develop the ...
The world's leading source for AI research, emerging technology, and the people building the future. Independent, rigorous, and always ahead.